Nantheia ATL5

Nantheia ATL5 is an investigational drug developed by ANANDA Scientific that combines cannabidiol (CBD) with their proprietary Liquid Structure delivery technology. It's being studied for several conditions including opioid use disorder, chronic pain, PTSD, and smoking cessation. The drug is formulated as an oral soft gel capsule containing 100mg of cannabidiol per capsule. Clinical trials are evaluating various dosages, including 200mg, 400mg, and 800mg daily regimens. The Liquid Structure technology is designed to enhance the effectiveness, consistent absorption, and stability of cannabidiol. The drug has received FDA approval for Investigational New Drug (IND) applications for these clinical studies. ANANDA Scientific positions this investigational drug as a potential non-addictive therapy for conditions where such options represent a significant unmet medical need. Pre-clinical and initial clinical studies suggest that the proprietary Liquid Structure delivery technology enhances CBD's effectiveness and stability, potentially creating new therapeutic applications for cannabidiol. The development of Nantheia ATL5 is supported by funding from the National Institute on Drug Abuse (NIDA).

Brand names

Nantheia ATL5

Other names

Nantheia™ ATL5